Samrat Pharmachem Ltd.

BSE: 530125 SECTOR: Pharmaceuticals & Drugs  13k   119   14

426.05
+8.60 (2.06%)
BSE: Today, 05:10 PM

Price Summary

Today's High

₹ 428.4

Today's Low

₹ 402

52 Week High

₹ 1250

52 Week Low

₹ 0

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

131.64 Cr.

Enterprise Value

121.89 Cr.

No. of Shares

0.31 Cr.

P/E

5.4

P/B

2.05

Face Value

₹ 10

Div. Yield

0.24 %

Book Value (TTM)

₹  207.77

CASH

17.27 Cr.

DEBT

7.52 Cr.

Promoter Holding

48.64 %

EPS (TTM)

₹  78.88

Sales Growth

23.9%

ROE

44.95 %

ROCE

52.33%

Profit Growth

222.22 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year23.9%
3 Year25.9%
5 Year24.98%

Profit Growth

1 Year222.22%
3 Year123.68%
5 Year57.83%

ROE%

1 Year44.95%
3 Year27.94%
5 Year22.16%

ROCE %

1 Year52.33%
3 Year32.89%
5 Year26.7%

Debt/Equity

0.1606

Price to Cash Flow

7.4

Interest Cover Ratio

35.991104521868

CFO/PAT (5 Yr. Avg.)

0.754012757661429

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2023 48.64 0
Dec 2022 48.64 0
Sep 2022 49.54 0
Jun 2022 49.65 0
Mar 2022 49.65 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 123.678956221261% for the Past 3 years.
  • The company has shown a good revenue growth of 25.9046345648128% for the Past 3 years.
  • Company has been maintaining healthy ROE of 27.9411908705393% over the past 3 years.
  • Company has been maintaining healthy ROCE of 32.8870088472301% over the past 3 years.
  • Company has a healthy Interest coverage ratio of 35.991104521868.
  • Company’s PEG ratio is 0.0243067654121175.
  • The company has an efficient Cash Conversion Cycle of 32.7275978369461 days.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 4.38768609940313.

 Limitations

 Looks like the company does not have any serious limitations.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022
Net Sales 55.58 60.16 86.51 71.12 84.11
Total Expenditure 46.74 49.99 73.62 62.86 80.57
Operating Profit 8.84 10.17 12.89 8.26 3.54
Other Income 0 0.09 0.03 0.16 0
Interest 0.13 0.17 0.23 0.24 0.6
Depreciation 0.15 0.15 0.16 0.16 0.16
Exceptional Items 0 -0.02 0 0 0
Profit Before Tax 8.56 9.91 12.53 8.02 2.77
Tax 2.11 2.92 3.16 2.11 0.68
Profit After Tax 6.45 7 9.37 5.91 2.1
Adjusted EPS (Rs) 20.86 22.64 30.31 19.13 6.78

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Net Sales 92.94 111.14 137.45 179.02 221.81
Total Expenditure 86.99 107.96 130.82 170.35 197.47
Operating Profit 5.95 3.18 6.63 8.67 24.34
Other Income 0.25 0.46 0.57 0.46 0.55
Interest 0.86 1.06 0.98 1.28 0.67
Depreciation 0.41 0.42 0.43 0.49 0.59
Exceptional Items 0 0 -0.01 -0.02 -0.02
Profit Before Tax 4.92 2.16 5.78 7.34 23.6
Tax 1.7 0.62 1.55 2.01 6.42
Net Profit 3.22 1.54 4.24 5.33 17.18
Adjusted EPS (Rs.) 10.41 4.97 13.71 17.26 55.62

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Equity and Liabilities
Share Capital 3.09 3.09 3.09 3.09 3.09
Total Reserves 15.44 16.98 21.21 26.55 43.73
Borrowings 0.76 0.63 0 0 0
Other N/C liabilities 0.51 0.52 0.14 0.43 0.46
Current liabilities 21.02 19.33 33.9 27.33 37.33
Total Liabilities 40.83 40.23 58.35 57.4 84.61
Assets
Net Block 6.99 6.86 7.19 9.4 9.99
Capital WIP 0 0 1.08 0 0
Intangible WIP 0 0 0 0 0
Investments 0 0 0 0 0
Loans & Advances 0.49 0.51 0.4 0.65 0.8
Other N/C Assets 0.08 0.1 0 0.02 0
Current Assets 33.27 32.76 49.68 47.32 73.82
Total Assets 40.83 40.23 58.35 57.4 84.61
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Profit from operations 4.92 2.16 5.79 7.34 23.6
Adjustment 1.17 1.4 1.39 1.7 1.19
Changes in Assets & Liabilities -5.08 0.47 -7.62 -1.99 -5.47
Tax Paid -0.88 -1.65 -0.87 -2.25 -1.53
Operating Cash Flow 0.13 2.37 -1.33 4.8 17.78
Investing Cash Flow -2.44 2.18 -1.92 -2.92 -1.37
Financing Cash Flow 1.53 -3.92 2 -1.89 -1.95
Net Cash Flow -0.78 0.63 -1.25 -0.02 14.46

Corporate Actions

Investors Details

PARTICULARS Mar 2022% Jun 2022% Sep 2022% Dec 2022% Mar 2023%
Promoters 49.65 49.65 49.54 48.64 48.64
lalit damodar mehta 13.74 13.74 13.74 13.70 13.70
rajesh lalit mehta 12.33 12.33 12.33 12.28 12.33
premal lalit mehta 5.64 5.64 5.64 5.64 5.64
kaushal lalit mehta 4.87 4.87 4.87 4.87 4.87
jaya lalit mehta 3.86 3.86 3.86 3.86 3.86
rupal rajesh mehta 2.58 2.58 2.58 2.37 2.58
kalpana premal meh... 2.24 2.24 2.24 2.24 2.24
falguni kaushal me... 2.15 2.15 2.15 2.15 2.15
megh rajesh mehta 1.38 1.38 1.38 1.19 1.38
maitri megh mehta - - - - -
PARTICULARS Mar 2022% Jun 2022% Sep 2022% Dec 2022% Mar 2023%
Investors 50.35 50.35 50.46 51.36 51.36
mala r bhavnani 5.20 5.20 5.20 5.20 5.20
subramanian p 4.07 4.07 4.07 4.14 4.07
sangeetha s - - - - -
lloyds securities ... 3.24 3.24 3.24 3.24 3.24
golechha global fi... - - - - -
alert consultants ... - - - - -
anshul specialty m... 1.33 1.33 1.33 1.33 1.33
sharad kanayalal s... 1.62 1.62 1.62 1.62 1.62
tina goyal - - - - -
llp - - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Samrat Pharmachem Stock Price Analysis and Quick Research Report. Is Samrat Pharmachem an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Samrat Pharmachem and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 17.7819 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Samrat Pharmachem has a Debt to Equity ratio of 0.1606 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Samrat Pharmachem , the EPS growth was 222.22556948532 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Samrat Pharmachem has OPM of 10.9747592214477 % which is a bad sign for profitability.
     
  • ROE: Samrat Pharmachem have a healthy ROE of 44.9521114013186 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Samrat Pharmachem

X